logo
  

PROG Holdings Boosts FY24 Outlook - Update

While reporting financial results for the first quarter on Wednesday, fintech holding company PROG Holdings, Inc. (PRG) provided financial outlook for the second quarter, and raised its earnings, adjusted earnings and revenue guidance for the full-year 2024.

For the second quarter, the company expects earnings in a range of $0.56 to $0.66 per share and adjusted earnings in a range of $0.65 to $0.75 per share on total revenues between $550 million and $575 million.

For fiscal 2024, the company now projects earnings in a range of $2.18 to $2.43 per share and adjusted earnings in a range of $2.85 to $3.10 per share on total revenues between $2.285 billion and $2.360 billion.

Previously, the company expected earnings in the range of $2.00 to $2.34 per share and adjusted earnings in the range of $2.70 to $3.00 per share on total revenues between $2.235 billion and $2.335 billion.

On average, five analysts polled by Thomson Reuters expect the company to report earnings of $2.86 per share on revenues of $2.32 billion for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft has launched a new category of Windows PCs designed for Artificial Intelligence (AI) that are slated to be the fastest and most intelligent Windows PCs ever built. The Copilot+ PCs come with built-in AI hardware and will support AI features across the operating system. Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit. While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings...

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT